Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market Jury awarded ...

The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After peaking at $341 in July, the stock plunged by over 25% to the current ...

With UPLIZNA receiving a label expansion that opens the door to a previously untapped rare disease market, Amgen is seeing strong returns on its USD 27.8 billion acquisition of Horizon Therapeutics.

Amgen has announced a total revenue of $8.5bn in Q3 2024, a 23% increase from a $6.9bn revenue in the same quarter of last year. The growth is driven by increased product sales by 24%, which ...

Many therapies aren't nearly as successful as hoped. Biotech giant Amgen (NASDAQ: AMGN) has had a harsh reminder of that reality in recent years. Some of its most recent brand-new launches ...

Amgen has announced a significant expansion of a manufacturing facility in the US state of Ohio, with an investment of $900m. The move brings the total investment in Central Ohio to more than $1 ...

Amgen's recent acquisition grants it a significant opportunity. The biotech is developing important medicines of its own. Amgen is also an excellent stock for income seekers. There are plenty of ...